# Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

> **NCT05694819** · PHASE2 · COMPLETED · sponsor: **National Cancer Center Hospital East** · enrollment: 57 (actual)

## Conditions studied

- Salivary Gland Cancer

## Interventions

- **DRUG:** Darolutamide
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT05694819
- **Lead sponsor:** National Cancer Center Hospital East
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-17
- **Primary completion:** 2024-08-09
- **Final completion:** 2026-03-23
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05694819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05694819, "Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05694819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*